Collaboration Revenue was Regeneron Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $7.33B of $14.34B (51%).
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Elyea Hd & Eylea | $6.26B | — | — | — | ||||
| Eylea | — | $5.72B | $4.77B | $2.75B | ||||
| Collaboration Revenue | $4.91B | $5.50B | $6.06B | $7.33B | ||||
| Other Collaboration Revenue | — | — | — | — | ||||
| Regen-Cov | — | — | — | — | ||||
| Sanofi Collaboration Revenue | — | — | — | — | ||||
| Elyea Hd | — | $165.80M | $1.20B | $1.64B | ||||
| Libtayo | $447.50M | $863.10M | $1.22B | $1.45B | ||||
| Other Revenue | $365.10M | $536.10M | $515.00M | $702.60M | ||||
| Product & Service, Other | — | — | — | — | ||||
| Praluent | $130.00M | $182.40M | $241.70M | $262.50M | ||||
| Evkeeza | $48.60M | $77.30M | $125.70M | $162.20M | ||||
| Inmazeb | $3.00M | $69.80M | $76.80M | $37.40M | ||||
| Arcalyst | — | — | — | — | ||||
| Other Products | — | — | — | $10.10M | ||||
| Total | $12.17B | $13.12B | $14.20B | $14.34B |
Regeneron Pharmaceuticals brought in $14.34B from its nine product and service lines in fiscal 2025, the year ended December 31, 2025. Regeneron Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $14.20B. Collaboration Revenue was the largest at $7.33B (51.1%), ahead of Eylea at $2.75B (19.2%) and Elyea Hd at $1.64B (11.4%). The other six lines brought in $2.63B combined.
Compared with fiscal 2024, Other Revenue grew fastest, up 36.4% to $702.60M, while Eylea fell the most, down 42.4% to $2.75B.
Regeneron Pharmaceuticals began breaking out Elyea Hd in fiscal 2023 and Other Products in fiscal 2025. Regeneron Pharmaceuticals stopped reporting Elyea Hd & Eylea as a separate line after fiscal 2022, when it brought in $6.26B.
As Previously Reported was Regeneron Pharmaceuticals’s largest revenue line in fiscal 2018, bringing in $6.71B of $5.15B (130%).
| Revision of Prior Period | FY 2018 |
|---|---|
| As Previously Reported | $6.71B |
| Adjustments | -$1.57B |
| Total | $5.15B |
Regeneron Pharmaceuticals brought in $5.15B from its two revenue lines in fiscal 2018, the year ended December 31, 2018. As Previously Reported was the largest at $6.71B (130.4%).
The total is net of Adjustments, which took $1.57B off revenue in fiscal 2018.
United States was Regeneron Pharmaceuticals’s largest region in fiscal 2023, bringing in $12.64B of $12.96B (97%).
| Geography | FY 2023 |
|---|---|
| United States | $12.64B |
| Non-Us | $324.30M |
| Total | $12.96B |
Regeneron Pharmaceuticals brought in $12.96B from its two regions in fiscal 2023, the year ended December 31, 2023. United States was the largest at $12.64B (97.5%), ahead of Non-Us at $324.30M (2.5%).
Regeneron Pharmaceuticals (REGN) reports its revenue by product and service, by revision of prior period and by geography. In fiscal 2025, Collaboration Revenue was its largest product and service line, bringing in $7.33B (51.1% of the total), followed by Eylea at $2.75B (19.2%).
Collaboration Revenue was Regeneron Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $7.33B, or 51.1% of the $14.34B total across its nine product and service lines.
As Previously Reported was Regeneron Pharmaceuticals' largest revenue line in fiscal 2018, bringing in $6.71B, or 130.4% of the $5.15B total across its two revenue lines.
United States was Regeneron Pharmaceuticals' largest region in fiscal 2023, bringing in $12.64B, or 97.5% of the $12.96B total across its two regions.
Every figure comes from Regeneron Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Regeneron Pharmaceuticals gives it, and years follow its fiscal calendar.
Regeneron Pharmaceuticals' revenue by product and service goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.